Showing 5121-5130 of 5644 results for "".
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- Iveric bio’s Zimura Meets its Primary Endpoint in a Phase 2b Trial in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bios-zimura-meets-its-primary-endpoint-in-a-phase-2b-trial-in-geographic-atrophy-secondary-to-dry-amd/2477046/Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a random
- CooperVision’s Michele Andrews, OD, Wins 2019 Theia Excellence Award from Women in Optometryhttps://modernod.com/news/coopervisions-michele-andrews-od-wins-2019-theia-excellence-award-from-women-in-optometry/2477045/For her significant contributions to the advancement of the industry and optometric profession, Michele Andrews, OD, Senior Director of Professional and Academic Affairs, North America, CooperVision, has been named a 2019 recipient of Women in Optometry’s Theia Excellence Awards. Dr. And
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- Oculus Teams Up With BHVI to Improve Myopia Managementhttps://modernod.com/news/oculus-teams-up-with-bhvi-to-improve-myopia-management/2477036/Oculus and BHVI (Brien Holden Vision Institute) have announced an agreement that will allow Oculus to incorporate BHVI’s algorithms for tracking and estimating refractive error into its Myopia Master ophthalmic instruments developed for the management of myopia.
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Julia A. Haller, MD, Elected to National Academy of Medicinehttps://modernod.com/news/julia-a-haller-md-elected-to-national-academy-of-medicine/2477033/Wills Eye Hospital announced its Ophthalmologist-in-Chief, Julia A. Haller, MD, has been elected to the National Academy of Medicine (NAM), considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement
- Johnson & Johnson Vision Releases Data From Study of Acuvue Oasys With Transitions Light Intelligent Technologyhttps://modernod.com/news/johnson-johnson-vision-releases-data-from-study-of-acuvue-oasys-with-transitions-light-intelligent-technology/2477034/Johnson & Johnson Vision announced new data from a study of its Acuvue Oasys with Transitions Light Intelligent Technology, which found the benefits of these first-of-its-kind light adaptive contact lens were deemed highly valued and useful by people who had never w
- Bausch Health Licenses Clearside Biomedical’s Xipere, An Investigational Treatment For Macular Edema Associated With Uveitishttps://modernod.com/news/bausch-health-licenses-clearside-biomedicals-xipere-an-investigational-treatment-for-macular-edema-associated-with-uveitis/2477035/Bausch Health Companies announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the United States and
- New Hope for Patients With Vision Loss at SAVIR-Center for Vision Restorationhttps://modernod.com/news/new-hope-for-patients-with-vision-loss-at-savir-center-for-vision-restoration/2477031/Persistent psychological stress, which is widely recognized as a consequence of vision loss, is also a major contributor to its development and progression, according to a study published in the EPMA Journal, the official journal of the European Association for Predictive, Preventive, and